Critical Survey: Avedro (NASDAQ:AVDR) and Bellicum Pharmaceuticals (NASDAQ:BLCM)

Avedro (NASDAQ:AVDR) and Bellicum Pharmaceuticals (NASDAQ:BLCM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Avedro and Bellicum Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avedro 0 3 3 0 2.50
Bellicum Pharmaceuticals 0 0 0 0 N/A

Avedro presently has a consensus target price of $21.20, indicating a potential downside of 5.15%. Given Avedro’s higher probable upside, analysts clearly believe Avedro is more favorable than Bellicum Pharmaceuticals.

Institutional & Insider Ownership

60.4% of Avedro shares are owned by institutional investors. Comparatively, 58.8% of Bellicum Pharmaceuticals shares are owned by institutional investors. 2.6% of Bellicum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Avedro and Bellicum Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avedro N/A N/A N/A
Bellicum Pharmaceuticals -4,081.44% -169.33% -88.47%

Valuation & Earnings

This table compares Avedro and Bellicum Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avedro $27.67 million 13.84 -$25.12 million ($17.97) -1.24
Bellicum Pharmaceuticals $1.12 million 44.60 -$98.04 million ($2.44) -0.44

Avedro has higher revenue and earnings than Bellicum Pharmaceuticals. Avedro is trading at a lower price-to-earnings ratio than Bellicum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Avedro beats Bellicum Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Avedro Company Profile

Avedro, Inc., an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations. Its Avedro Corneal Remodeling platform treats corneal ectatic disorders and corrects refractive conditions; and KXL system in combination with Photrexa drug formulations used for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products through a direct sales force in the United States and through medical device distributors internationally. The company was formerly known as ThermalVision, Inc. and changed its name to Avedro, Inc. in October 2005. Avedro, Inc. was incorporated in 2002 and is headquartered in Waltham, Massachusetts.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.